TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32009466

Group type: EXPERIMENTAL
Intervention: Crowdsourcing engagement activities for informed consent process
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Crowdsourcing engagement activities for experience of trial participation
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Crowdsourcing idea contest for fairness/reciprocity in HIV clinical trials
Number of subjects: 81
Study: 32009824

Group type: EXPERIMENTAL
Intervention: Alectinib
Number of subjects: 0
Study: 32010048

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 32010057

Group type: EXPERIMENTAL
Intervention: Intra-neuroendoscopic technique
Number of subjects: 0
Study: 32010577

Group type: EXPERIMENTAL
Intervention: IBI305
Number of subjects: 450

Group type: COMPARATOR
Intervention: Bevacizumab
Number of subjects: 450
Study: 32010719

Group type: EXPERIMENTAL
Intervention: Dupilumab 200 mg every 2 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 2 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32010755

Group type: EXPERIMENTAL
Intervention: Percutaneous transhepatic biliary drainage
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 32011475

Group type: EXPERIMENTAL
Intervention: Resting state functional magnetic resonance imaging (fALFF) in PI patients
Number of subjects: 30
Study: 32011678

Group type: EXPERIMENTAL
Intervention: HANT archwires
Number of subjects: 31

Group type: COMPARATOR
Intervention: SENT archwires
Number of subjects: 31
Study: 32011909

Group type: EXPERIMENTAL
Intervention: SPT-Intense (3 hourly sessions per day/3 days per week)
Number of subjects: 12

Group type: COMPARATOR
Intervention: SPT-T (1 hour-long session per day/3 days per week)
Number of subjects: 12
Study: 32011914

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 32012039

Group type: EXPERIMENTAL
Intervention: Telehealth-Delivered Pulmonary Rehabilitation Intervention
Number of subjects: 0
Study: 32012106

Group type: EXPERIMENTAL
Intervention: Various treatments for UTUC (specific treatments not detailed)
Number of subjects: 2451

Group type: COMPARATOR
Intervention: Not applicable (observational study)
Number of subjects: 2451
Study: 32012111

Group type: EXPERIMENTAL
Intervention: 2GETHER USA intervention (relationship education and HIV prevention program)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Control condition (existing public health practice)
Number of subjects: 280
Study: 32012114

Group type: EXPERIMENTAL
Intervention: Nurse-delivered cognitive behavioral therapy (CBT-AD) for adherence and depression; 8 sessions.
Number of subjects: 160

Group type: COMPARATOR
Intervention: Enhanced treatment as usual (control group).
Number of subjects: 160
Study: 32012116

Group type: EXPERIMENTAL
Intervention: Medly (mobile phone-based telemonitoring system) in addition to standard of care
Number of subjects: 144

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 144
Study: 32012159

Group type: EXPERIMENTAL
Intervention: On-line hemodiafiltration (HDF)
Number of subjects: 60

Group type: COMPARATOR
Intervention: High-flux hemodialysis (HD)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups (HDF and HD)
Number of subjects: 60
Study: 32012214

Group type: EXPERIMENTAL
Intervention: Loncastuximab tesirine at 15 to 150 μg/kg IV once every 3 weeks (Q3W) or 50 μg/kg IV weekly.
Number of subjects: 35
Study: 32012230

Group type: EXPERIMENTAL
Intervention: Rituximab only
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Rituximab and lenalidomide/Revlimid®
Number of subjects: 154
Study: 32012763

Group type: EXPERIMENTAL
Intervention: RGB-D camera measurements
Number of subjects: 30
Study: 32013314

Group type: EXPERIMENTAL
Intervention: PF-00547659
Number of subjects: 265

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 265
Study: 32013703

Group type: EXPERIMENTAL
Intervention: Elevated homocysteine
Number of subjects: 6789
Study: 32013707

Group type: EXPERIMENTAL
Intervention: Functionally Optimized Coronary Intervention (FCI) using an optical-sensor pressure wire
Number of subjects: 226
Study: 32013865

Group type: EXPERIMENTAL
Intervention: Zero-fluoroscopy approach (ZF)
Number of subjects: 1020

Group type: COMPARATOR
Intervention: Conventional fluoroscopy approach (CF)
Number of subjects: 1020
Study: 32013994

Group type: EXPERIMENTAL
Intervention: Modelled geographical access (P) using GIS tools (ArcGIS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-reported travel times (R)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modelled travel times to the actual facilities accessed (A)
Number of subjects: 0
Study: 32013996

Group type: EXPERIMENTAL
Intervention: Moves app
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Survey responses
Number of subjects: 274
Study: 32013998

Group type: EXPERIMENTAL
Intervention: MOCO cines
Number of subjects: 149
Study: 32014005

Group type: EXPERIMENTAL
Intervention: Shear wave ultrasound elastography (SWE)
Number of subjects: 560
Study: 32014041

Group type: EXPERIMENTAL
Intervention: Post-traumatic cerebral infarction (PTCI)
Number of subjects: 143

Group type: COMPARATOR
Intervention: IMPACT core model without PTCI
Number of subjects: 143

Group type: COMPARATOR
Intervention: IMPACT extended model without PTCI
Number of subjects: 143
Study: 32014287

Group type: EXPERIMENTAL
Intervention: Zenith Alpha thoracic endovascular graft (Cook Medical)
Number of subjects: 50
Study: 32014432

Group type: EXPERIMENTAL
Intervention: PROGALIAM (2006-2013)
Number of subjects: 6783

Group type: COMPARATOR
Intervention: Pre-PROGALIAM (2001-2005)
Number of subjects: 6783
Study: 32014871

Group type: EXPERIMENTAL
Intervention: Caregivers of PLH children
Number of subjects: 77
Study: 32015000

Group type: EXPERIMENTAL
Intervention: Patients with newly identified mutations in MCPH
Number of subjects: 7
Study: 32015090

Group type: EXPERIMENTAL
Intervention: Intravenous rt-PA
Number of subjects: 944
Study: 32015419

Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination treatment of tolvaptan and pioglitazone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 0
Study: 32015566

Group type: EXPERIMENTAL
Intervention: Cardiac valve surgery with infective endocarditis (IE)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cardiac valve surgery without infective endocarditis (control)
Number of subjects: 40
Study: 32016127

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART) for 3 years
Number of subjects: 143
Study: 32016390

Group type: EXPERIMENTAL
Intervention: MRDTI negative for DVT
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: MRDTI readings
Number of subjects: 305
Study: 32016415

Group type: EXPERIMENTAL
Intervention: RYGB
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: SG
Number of subjects: 42
Study: 32016427

Group type: EXPERIMENTAL
Intervention: AMH in early postmenarchal girls (5.2 ± 0.3 ng/mL)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: AMH in girls with ovulatory cycles
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Correlation of AMH with ln_LH
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Correlation of AMH with ln_androstenedione
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Correlation of AMH with ln_testosterone
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Correlation of AMH with ovarian volume
Number of subjects: 23

Group type: COMPARATOR
Intervention: Correlation of AMH in women with estradiol
Number of subjects: 23

Group type: COMPARATOR
Intervention: Correlation of AMH in women with P4
Number of subjects: 23
Study: 32016528

Group type: EXPERIMENTAL
Intervention: Protocol group (Group Pro)
Number of subjects: 35
Study: 32016643

Group type: EXPERIMENTAL
Intervention: Dietary questionnaire for caffeine intake estimation
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: 24-h urinary excretion measurement
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Correlation analysis between self-reported intake and urinary excretion
Number of subjects: 91
Study: 32016676

Group type: EXPERIMENTAL
Intervention: Low CXCL10 expression
Number of subjects: 3763

Group type: EXPERIMENTAL
Intervention: Downregulated CXCL10 expression
Number of subjects: 3763
Study: 32017044

Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 2233
Study: 32017341

Group type: EXPERIMENTAL
Intervention: Ulimorelin 600-1200 µg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ulimorelin 150-600 µg/kg
Number of subjects: 0
Study: 32017433

Group type: EXPERIMENTAL
Intervention: Individualized appropriate medical therapy (AMT)
Number of subjects: 39
Study: 32017652

Group type: EXPERIMENTAL
Intervention: ctHPVDNA surveillance
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: ctHPVDNA positivity in two consecutive plasma samples
Number of subjects: 115
Study: 32019278

Group type: EXPERIMENTAL
Intervention: Anthracycline-Taxane-Based Neoadjuvant Chemotherapy
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Carboplatin-containing treatment
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Multivariable analysis
Number of subjects: 92
Study: 32019333

Group type: EXPERIMENTAL
Intervention: Maternal linkage to care after intervention
Number of subjects: 87

Group type: COMPARATOR
Intervention: Paternal testing for HIV
Number of subjects: 87

Group type: COMPARATOR
Intervention: Paternal linkage to care
Number of subjects: 87

Group type: COMPARATOR
Intervention: Paternal on ART
Number of subjects: 87
Study: 32019508

Group type: EXPERIMENTAL
Intervention: Minneapolis stores post-policy compliance measures
Number of subjects: 155

Group type: COMPARATOR
Intervention: St. Paul stores post-policy compliance measures
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Corporate stores in Minneapolis
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Neighborhood characteristics in compliance measures
Number of subjects: 155
Study: 32019538

Group type: EXPERIMENTAL
Intervention: Cystic areas (CCAM)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control areas
Number of subjects: 11
Study: 32019550

Group type: EXPERIMENTAL
Intervention: MO with OSA without CPAP
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: MO with OSA and CPAP
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: MO without OSA
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (participants in the EPIOSA study)
Number of subjects: 45
Study: 32019577

Group type: EXPERIMENTAL
Intervention: Neuropsychological test battery (six tests)
Number of subjects: 45
Study: 32019596

Group type: EXPERIMENTAL
Intervention: 38% Silver Diamine Fluoride (SDF) solution
Number of subjects: 730

Group type: COMPARATOR
Intervention: 5% Sodium Fluoride (NaF) varnish
Number of subjects: 730
Study: 32019635

Group type: EXPERIMENTAL
Intervention: Therapist training in positive behaviour support (PBS)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 246
Study: 32020437

Group type: EXPERIMENTAL
Intervention: RO6839921 (inactive pegylated prodrug of idasanutlin) administered at doses of 120-300 mg, with maximum tolerated dose (MTD) identified as 200 mg.
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: RO6839921 (inactive pegylated prodrug of idasanutlin) administered at doses of 120-300 mg.
Number of subjects: 26
Study: 32020889

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 282

Group type: COMPARATOR
Intervention: Sham electroacupuncture (SA)
Number of subjects: 282

Group type: COMPARATOR
Intervention: Solifenacin
Number of subjects: 282
Study: 32021066

Group type: EXPERIMENTAL
Intervention: Baerveldt-350 glaucoma implant (BGI)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Ahmed glaucoma implant (AGV-S2 and FP7 models)
Number of subjects: 81
Study: 32021070

Group type: EXPERIMENTAL
Intervention: iStent inject implantation
Number of subjects: 57
Study: 32021227

Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan
Number of subjects: 0

Group type: COMPARATOR
Intervention: enalapril
Number of subjects: 0
Study: 32021387

Group type: EXPERIMENTAL
Intervention: Low-dose manual acupuncture (MAL)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: High-dose manual acupuncture (MAH)
Number of subjects: 57
Study: 32021407

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg/day
Number of subjects: 353

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 353
Study: 32021411

Group type: EXPERIMENTAL
Intervention: Meloxicam IV 30 mg
Number of subjects: 379

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 379
Study: 32021913

Group type: EXPERIMENTAL
Intervention: Nitroglycerin (Transiderm-Nitro 5 patch) during radiotherapy
Number of subjects: 42
Study: 32022390

Group type: EXPERIMENTAL
Intervention: TAVI intervention
Number of subjects: 2160

Group type: EXPERIMENTAL
Intervention: TAVI futility risk model
Number of subjects: 2160
Study: 32022437

Group type: EXPERIMENTAL
Intervention: Pediatric sized supraglottic airways designed for intubation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Videolaryngoscopy and combination techniques for intubation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Techniques for maintaining oxygenation during intubation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Airway management techniques in patients at risk for aspiration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Considerations in cannot intubate cannot oxygenate scenarios
Number of subjects: 0
Study: 32022621

Group type: EXPERIMENTAL
Intervention: T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL)
Number of subjects: 0
Study: 32022692

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral therapy program (Breathe)
Number of subjects: 536

Group type: COMPARATOR
Intervention: Anxiety-based resource webpages (control)
Number of subjects: 536

Group type: EXPERIMENTAL
Intervention: Breathe respondents' perceived change in anxiety
Number of subjects: 536
Study: 32022781

Group type: EXPERIMENTAL
Intervention: eHealth platform for nutrition interventions
Number of subjects: 21
Study: 32023303

Group type: EXPERIMENTAL
Intervention: Stepped care
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Collaboration
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Barriers to collaboration
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Needs for stepped care
Number of subjects: 20
Study: 32023374

Group type: EXPERIMENTAL
Intervention: HLA-mismatched anti-CD19 CAR-NK cells derived from cord blood
Number of subjects: 11
Study: 32024079

Group type: EXPERIMENTAL
Intervention: Gut microbiome of RTRs
Number of subjects: 139

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 139
Study: 32024468

Group type: EXPERIMENTAL
Intervention: Single nucleotide polymorphisms (SNPs) in SCN9A, SCN10A, and SCN11A
Number of subjects: 198
Study: 32024471

Group type: EXPERIMENTAL
Intervention: Not taking statins
Number of subjects: 1127

Group type: EXPERIMENTAL
Intervention: Physical inactivity
Number of subjects: 1127

Group type: EXPERIMENTAL
Intervention: Peripheral artery disease
Number of subjects: 1127

Group type: EXPERIMENTAL
Intervention: Chronic kidney failure
Number of subjects: 1127

Group type: EXPERIMENTAL
Intervention: Former smoking
Number of subjects: 1127

Group type: EXPERIMENTAL
Intervention: Higher Hospital Anxiety and Depression Scale-Depression subscale score
Number of subjects: 1127

Group type: EXPERIMENTAL
Intervention: Preventable and potentially modifiable factors
Number of subjects: 1127

Group type: EXPERIMENTAL
Intervention: Smoking, low physical activity, not taking statins, not participating in cardiac rehabilitation, diabetes
Number of subjects: 1127
Study: 32024473

Group type: EXPERIMENTAL
Intervention: Intervention group (n=1500)
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Control group (n=500)
Number of subjects: 2000
Study: 32024528

Group type: EXPERIMENTAL
Intervention: Equilibrium method
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Average method
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Full method
Number of subjects: 34

Group type: COMPARATOR
Intervention: No compensation reference
Number of subjects: 34
Study: 32024586

Group type: EXPERIMENTAL
Intervention: MATRx plus home sleep apnea test (HSAT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MATRx plus HSAT
Number of subjects: 0
Study: 32024675

Group type: EXPERIMENTAL
Intervention: Lower extremity MR biomarkers (muscle fat fraction and MRI T2)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Lower extremity MR biomarkers from proximal muscles
Number of subjects: 160
Study: 32024786

Group type: EXPERIMENTAL
Intervention: Multicomponent menstrual health management (MHM) intervention including teacher training, menstrual kit use, pain management, drama skit, provision of analgesics, and improvements to school facilities.
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Multicomponent menstrual health management (MHM) intervention.
Number of subjects: 450
Study: 32025570

Group type: EXPERIMENTAL
Intervention: Artesunate and dihydroartemisinin
Number of subjects: 0
Study: 32025589

Group type: EXPERIMENTAL
Intervention: Topical tacrolimus 0.05%
Number of subjects: 4
Study: 32025615

Group type: EXPERIMENTAL
Intervention: Pea Hull Fiber (PHF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 32025629

Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (native joints and OJA)
Number of subjects: 20
Study: 32025741

Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA treatment (shoulder injections)
Number of subjects: 140

Group type: COMPARATOR
Intervention: No shoulder treatment (control group)
Number of subjects: 140
Study: 32025755

Group type: EXPERIMENTAL
Intervention: Urinary C-C motif chemokine ligand 14 (CCL14)
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Urinary KIM-1
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Plasma cystatin C
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Urinary NGAL
Number of subjects: 364
Study: 32025764

Group type: EXPERIMENTAL
Intervention: Vancomycin-soaked grafts (Group 2)
Number of subjects: 1674

Group type: COMPARATOR
Intervention: No vancomycin (Group 1)
Number of subjects: 1674

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 1674
Study: 32026092

Group type: EXPERIMENTAL
Intervention: Contingency Management Condition (CMC)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Usual Care Condition (UCC)
Number of subjects: 16
Study: 32026120

Group type: EXPERIMENTAL
Intervention: Percutaneous Deep Vein Arterialization (pDVA) using LimFlow System
Number of subjects: 50
Study: 32026243

Group type: EXPERIMENTAL
Intervention: Pirfenidone, administered in three divided doses daily, median dose 2400 mg/day, exposure duration median 3.0 years.
Number of subjects: 83
Study: 32026327

Group type: EXPERIMENTAL
Intervention: Dynamic PET/CTA myocardial blood flow assessment with fused imagery (DEMYSTIFY)
Number of subjects: 108
Study: 32026347

Group type: EXPERIMENTAL
Intervention: Pirfenidone, mean (SD) daily dose 2058.7 (399.2) mg, mean (SD) exposure 22.8 (9.6) weeks
Number of subjects: 1620
Study: 32026407

Group type: EXPERIMENTAL
Intervention: Vismodegib 150 mg plus pirfenidone 2403 mg/day once daily
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 21
Study: 32026411

Group type: EXPERIMENTAL
Intervention: Ambroxol 20 mg hard-boiled lozenges
Number of subjects: 390

Group type: COMPARATOR
Intervention: Placebo hard-boiled lozenges
Number of subjects: 390
Study: 32026446

Group type: EXPERIMENTAL
Intervention: Mechanical ventilation for acute stroke patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Decisions to withhold or withdraw care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: mRS scores at 3 and 6 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Health-related quality of life at 1 year
Number of subjects: 0
Study: 32026743

Group type: EXPERIMENTAL
Intervention: Patient reports of pain interference
Number of subjects: 0

Group type: COMPARATOR
Intervention: Informal caregiver proxy reports of pain interference
Number of subjects: 0
Study: 32026814

Group type: EXPERIMENTAL
Intervention: Initial assessment (<72 hours)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Follow-up (8-10 weeks)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Soft tissue palpation and Neer's Test
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Therapy interventions
Number of subjects: 121
Study: 32026830

Group type: EXPERIMENTAL
Intervention: Aerobic training and localised training for upper and lower limbs conducted for 24 sessions, three times per week
Number of subjects: 77
Study: 32027796

Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 1373

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 1373

Group type: EXPERIMENTAL
Intervention: Probucol
Number of subjects: 1373

Group type: COMPARATOR
Intervention: Non-probucol
Number of subjects: 1373

Group type: EXPERIMENTAL
Intervention: Cilostazol and Probucol
Number of subjects: 1373
Study: 32027846

Group type: EXPERIMENTAL
Intervention: Osimertinib 80 mg plus savolitinib 600 mg daily (part B)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Osimertinib 80 mg plus savolitinib 300 mg daily (part D)
Number of subjects: 186
Study: 32027845

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 32027858

Group type: EXPERIMENTAL
Intervention: FAST score (FibroScan-AST) using LSM, CAP, and AST
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: FAST score (FibroScan-AST) in external validation cohorts
Number of subjects: 350
Study: 32028209

Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg every 2 weeks until progression or unacceptable toxicity
Number of subjects: 811
Study: 32028493

Group type: EXPERIMENTAL
Intervention: Fetoscopic tracheal balloon occlusion
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Vaginal progesterone
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Tocolytics
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Vaginal pessary placement
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Amnioreduction
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Gestational age at birth
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: High-frequency ventilation
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Extracorporeal membrane oxygenation
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Neonatal survival
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Survival to hospital discharge
Number of subjects: 14
Study: 32028921

Group type: EXPERIMENTAL
Intervention: Naloxone distribution program with overdose prevention education
Number of subjects: 2000